CureVac Stock Soars on BioNTech Buyout

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion. The merger is still awaiting review from the German Economy Ministry.Today's pop has CVAC trading at 52-week highs, conquering resistance at the $5 level, which kept it in penny stock territory for the last year. Since the start of 2025, the equity is up 63.5%. CureVac stock's typically quiet options pits are booming today. The stock has alre ...